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Available online 16 April 2016Background: Plasma B-type natriuretic peptide (BNP) levels may vary widely among patients with similar stages
of heart failure, inwhom obesity might be the only factor reducing plasma BNP levels. We investigated the effect
of obesity and body mass index (BMI) on plasma BNP levels using serial measurements before and after
treatment (pre- and post-BNP and pre- and post-BMI) in patients with acute heart failure.
Methods:Multiple regression analysis and covariance structure analysiswere performed to study the interactions
between clinical factors in 372 patients. The pre-BMI was shown as a combination index of obesity and ﬂuid
accumulation, whereas the post-BMI was a conventional index of obesity.
Results: There was a signiﬁcant inverse correlation between BMI and BNP in each condition before and after
treatment for heart failure. The direct signiﬁcant associations of the log pre-BNP with the log post-BNP (β:
0.387), the post-BMI (β: −0.043), and the pre-BMI (β: 0.030) were analyzed by using structural equation
modeling. The post-BMI was inversely correlated, but importantly, the pre-BMI was positively correlated, with
the log pre-BNP, because the pre-BMI probably entailed an element of ﬂuid accumulation. There were few
patients with extremely high levels of pre-BNP among those with high post-BMI, due to suppressed secretion
of BNP.
Conclusions: The low plasma BNP levels in true obesity patients with acute heart failure are of concern, because
plasma BNP cannot increase in such patients.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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B-type or brain natriuretic peptide (BNP) is one of the natriuretic
peptides and is widely used for diagnosis and predicting prognosis in
heart failure [1–5]. Although the plasma BNP level is thought to be a
good biochemical marker of heart failure, the levels may vary widely
among patients in whom the severity of heart failure is clinically in
the same range [6]. The wide range of plasma BNP levels may be
explained by a number of factors contributing to the secretion of BNP,
which differ among individuals and vary according to conditions.
Among the factors contributing to plasma BNP levels, ventricular
hemodynamic overload signiﬁcantly stimulates the secretion of BNP;
combined ventricular dysfunction and associated body ﬂuid overload
are the major stimulating factors [2,3]. Volume overload induced by
renal dysfunction is another major contributor to increased plasma
BNP levels. Aging and male sex also inﬂuence plasma BNP levels [7].partment of Internal Medicine,
mbashi, Minato-ku, Tokyo 105-
land Ltd. This is an open access articlNeurohumoral factors, the renin–angiotensin–aldosterone (RAA) sys-
tem, endothelin-1, oxidative stress, inﬂammatory cytokines, and others
can increase plasma BNP levels [8–10]. The conditions associated with
these factors ﬁnely modulate plasma BNP levels according to the individ-
ual. In circumstances such as these, it is interesting to note that the above
factors are almost all positive regulators of plasma BNP levels; the nega-
tive regulatory factors are rare. Fat accumulation/obesity may be the
only applicable factor decreasing plasma BNP levels. However, the true
impact of obesity on plasma BNP levels has not yet been clariﬁed. It is un-
certain whether obesity per se has a major impact on plasma BNP levels.
It is possible that the main cause of the wide range of plasma BNP
levels in clinically similar stages of heart failure may be the result of
habitus, with obesity or slenderness contributing to the development of
heart failure. Plasma BNP levels are likely to increase in slenderness but
not in obesity among patients with heart failure. To precisely determine
the effect of obesity on plasma BNP levels, it is necessary to identify a suit-
able marker of fat accumulation/obesity during heart failure.
Body mass index (BMI) is the simplest and best marker of fat
accumulation or obesity in general; however, the BMI of a patient
with heart failure represents not only fat accumulation/obesity but
also body ﬂuid excess due to heart failure, because BMI is calculated ase under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mulation due to cardiac dysfunction would further augment cardiac
overload and thereafter tends to increase plasma BNP levels, whereas
obesity itself decreases plasma BNP levels. Therefore, the BMI before
treatment (pre-BMI) was used as a combined index of obesity and
ﬂuid accumulation for descriptive purposes in this study, whereas the
BMI after treatment (post-BMI) was an index of obesity, as convention-
ally applied. To the best of our knowledge, no study has focused on the
true effect of obesity on plasma BNP levels during the “wet” period by
using the BMI during the “dry” period.
Another impediment to this type of analysis is statistical computing
intractableness. Theoretically, the secretion of BNP is inﬂuenced by
many factors at all times. It is thus quite logical to simultaneously in-
clude every possible factor including ﬂuid accumulation into the same
analysis. It might thus be preferable in this study to use BMI before
treatment as a component of the same equation, because it partially
represents ﬂuid accumulation. However, the BMI before treatment
would surely be confounded with the BMI after treatment, and
therefore, multiple regression analysis cannot be applied simultaneous-
ly. Furthermore, many other clinical factors related to each other would
simultaneously inﬂuence plasma BNP levels. Simultaneous comparison
of the inﬂuence of possible factors affecting plasma BNP levels requires
highly technical computing; covariance structure analysis or data-
mining technology would be required for this complex statistical
analysis.
We investigated the impact of obesity on plasma BNP levels by using
a path analysis based on covariance structure analysis in patients
admitted to our institution with acute heart failure. Among
hemodynamic parameters and blood samples measured serially during
treatment, we used two data points: before and after the treatment of
acute heart failure.
2. Methods
2.1. Study patients
The study population consisted of 372 consecutive patients hospital-
ized due to acute heart failure between 2012 and 2014 at Jikei Universi-
ty Hospital. The sampling data included BMI and plasma BNP levels on
admission before treatment, and after intensive treatment for acute
heart failure. We excluded patients with acute myocardial infarction
(AMI), because plasma BNP levels noticeably and rapidly increase dur-
ing the24h after onset of AMI in amonophasicmanner, then transiently
decrease, possibly followed by another increase two to three days after
onset (depending on the degree of ventricular remodeling), thus
resulting in a biphasic proﬁle [11]. Patients who required emergency
surgery, including coronary artery bypass and noncardiac surgery, dur-
ing the period between the collection of theﬁrst and secondplasmaBNP
samples were also excluded. The study protocol (27–243 [8128]) was
approved by the Ethics Committee of The Jikei University School of
Medicine, and we complied with the routine ethical regulations of our
institution. This is a retrospective study and informed consent could
not be obtained from each patient. Instead of obtaining informed con-
sent from each patient, we posted a notice about the study design and
contact information at a public location in our institution.
2.2. Diagnosis of acute heart failure
Acute heart failurewas diagnosed according to the guidelines for the
treatment of acute heart failure published by the Japanese Circulation
Society. Patients with heart failure symptoms (New York Heart
Association [NYHA] functional class II to IV) underwent several exami-
nations (blood gas analysis, blood sampling, electrocardiogram, plain
chest radiography, and echocardiogram), and agreed to be admitted to
our hospital.2.3. Treatment of acute heart failure
The patients were treatedwith drugs, such as diuretics, angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, aldoste-
rone antagonists, beta blockers, nitrates, carperitide (humanatrial natri-
uretic peptide), and, if necessary, catecholamines and mechanical
support such as respirators, intra-aortic balloon pumping, or percutane-
ous cardiopulmonary support.2.4. Blood sampling and measurement of plasma BNP and other levels
We collected data for plasma BNP and other levels. The ﬁrst sample
was obtained immediately after admission and before intensive
treatment (pre-BNP). In each case, the second sample was collected
when the clinical symptoms of acute heart failure improved and the
patient's condition stabilized. Whole blood (5 mL) was collected in
tubes containing potassium ethylenediaminetetraacetic acid (EDTA)
(1 mg/mL blood). Plasma BNP was measured with a rapid enzyme-
linked immunosorbent assay (nonextracted) using an antibody to
human BNP (Shionogi Co. Ltd., Tokyo, Japan). Serum biochemical analy-
ses including creatinine (Cr) were performed in a central laboratory in
our hospital during the study.2.5. Echocardiographic examination and other measurements
An echocardiographic examination was performed in all patients
by three expert cardiologists, and left ventricular ejection fraction
(LVEF) was used as a marker of systolic dysfunction. BMI was
calculated on the basis of height and weight on admission and after
therapy.2.6. Statistical analysis
Continuous variables were expressed as themeans± standard devi-
ation (SD) or medians. The correlation between two factors was
expressed as Spearman's correlation coefﬁcient and single regression
analysis. Multiple regression analysis was performed when multiple
values were compared. In the multivariate analysis, natural logarithmic
conversion (log) was performed on the BNP values, because they were
not normally distributed. A chi-squared analysis was applied for a test
for comparison between two groups, if it is necessary. Statistical analy-
ses were performed using SPSS Statistics version 23.0 (SPSS Inc., Chica-
go, IL, USA), and differences were considered to be statistically
signiﬁcant for P-values b 0.05.
Path analysis was used to investigate the relation between
clinical factors in this study population and especially to survey
probable causal effects on the plasma BNP levels before the treat-
ment. Path analysis was performed with IBM SPSS AMOS version
23 (Amos Development Corporation, Meadville, PA, USA) [12]. The
obtained structural equation models were tested and conﬁrmed at
the signiﬁcance level for P-values b 0.05. The causality model deﬁnes
some hierarchical regression models between clinical factors and the
plasma BNP levels. Paths between variables are drawn from
independent to dependent variables with directional arrow for
every regression model (arrowhead on one end only). A two-way
arrow between two variables indicates the correlation between
these two variables. For every regression, the total variance in
dependent variable is theorized to be caused either by independent
variables of the model or by extraneous variables (e). Each path
has a coefﬁcient showing the standardized coefﬁcient of regressing
independent variable on dependent variable of the relevant path. The
indirect effect was determined by multiplying the path coefﬁcients of
intervening variables.
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3.1. Study population
The baseline characteristics of the study population are shown in
Table 1. No patients died during therapy and the clinical symptoms of
acute heart failure were successively improved by intensive treatment,
although the remediation levels varied among the patients. This study
included 51 patients (13.7%) in NYHA functional class II, 196 patients
(52.7%) in class III and 125 patients (33.6%) in class IV among 372 pa-
tients in total. The period between the two points of sampling was
19.1 ± 12.3 days (3 days minimally and 91 maximally).
3.2. Single regression analysis for the determination of the impact of BMI on
the plasma BNP levels in each phase, before and after the treatment
By the single regression analysis, there was a signiﬁcant correlation
between the pre-BMI and the log pre-BNP and between the post-BMI
and the log post-BNP as shown in Fig. 1A and B (P b 0.001, respectively).
This suggests that the BMI seemingly affected the plasma BNP levels
before and after the treatment.
3.3. Multiple regression analysis for a determination of the impact of BMI on
the plasma BNP levels in each phase, before and after the treatment
To examine the effect of the BMI on the plasma BNP levels, the
multivariable regression analysis was performed; and the analysis
identiﬁed the pre-BMI as an independent negative correlate of the log
pre-BNP (Table 2A). Other independent correlates included female
gender, age, the serum creatinine levels and the LVEF, and these factors
were signiﬁcantly associated with the log pre-BNP as independent
positive correlated factors. Also, anothermultivariate analysis identiﬁed
that the post-BMI as an independent negative correlate of the log
post-BNP (Table 2B). Other independent correlates included female
gender, age, the serum Cr levels and the LVEF, and these factors were
signiﬁcantly associated with the log post-BNP as independent positive
correlated factors. These multivariate analyses would also conﬁrm the
previous ﬁndings that obesity was inversely associatedwith the plasma
BNP levels.
Nonetheless, the impact of true obesity on the plasma BNP levels in
the acute phase of heart failure would be still unclear using multipleTable 1
The characteristics of all patients.
Characteristics (n = 372) Overall; mean ± SD (median) [interquartile range]
Gender: male/female 267/105
Age (years old) 68.4 ± 15.2
BMI (kg/m2) 23.8 ± 4.7 (23.1) [13.7–46.0]
Creatinine (mg/dL) 1.34 ± 1.02
CRP (mg/dL) 1.01 ± 1.52
BNP (pg/mL) 939.8 ± 899.3 (671.1) [17.6–8274.1]
Log BNP 2.82 ± 0.37 (2.83) [1.25–3.92]
NYHA class [I/II/III/IV] (%) 3.2 ± 0.7 [0/51/196/125] (0%/13.7%/52.7%/33.6%)
LVEF (%) 40.6 ± 15.8
Underlying cardiovascular disease number (% of overall)
Ischemic heart disease 42 (11.9%)
Congestive heart failure 231 (62.5%)
Arrhythmia 26 (7.0%)
Cardiomyopathy 47 (11.1%)
Valvular disease 26 (7.5%)
Hypertension 230 (61.8%)
Type 2 diabetes mellitus 125 (33.7%)
Dyslipidemia 196 (52.8%)
Renal dysfunctiona 254 (68.3%)
BMI, bodymass index; BNP, B-type natriuretic peptide; eGFR, estimated glomerular ﬁltra-
tion rate; CRP, C-reactive protein; NYHA class, NewYorkHeart Association functional clas-
siﬁcation; LVEF, left ventricular ejection fraction.
a Renal dysfunction means eGFR of b60 mL/min/1.73 m2.regression analysis alone because the plasma BNP levels in the acute
phase of heart failure are inﬂuenced by obesity and ﬂuid accumulation
in a complex manner, as shown in Fig. 2. Multiple regression analysis
would have a limitation in comparing the true relationship between
obesity and plasma BNP levels before treatment; it was unfortunate
that multivariate analysis by simultaneous inclusion of both pre-BMI
and post-BMI in one equation is inappropriate because pre-BMI and
post-BMI were the confounding variables (P b 0.001), as shown in
Table 3.
3.4. Analysis of an association between obesity and plasma BNP levels in the
acute phase of heart failure by covariance structure analysis
In order to examine the true impact of obesity on plasma BNP levels
in the acute phase of heart failure, we conducted path analysis based on
covariant structure analysis. To clarify the factors truly inﬂuencing the
log pre-BNP, the theoretical pass model was ﬁrst proposed, as shown
in Fig. 3A; this model was constructed based on theoretical concerns
and by reference to Pearson's correlation coefﬁcient as shown in
Table 3. Log pre-BNP lay centrally in the path model. Log pre-BNP
must be affected by log post-BNP, and pre-BMI must also be affected
by post-BMI. Log pre-BNP would be affected by not only pre-BMI but
also post-BMI,whichwas themain focus of this study. Other parameters
including age, gender, pre-Cr, post-Cr and LVEF were proposed as
potential factors affecting log pre-BNP. Pre-Cr would be associated
with post-Cr. After the ﬁrst analysis (Table 4A), we found that the
contribution of age and gender on log pre-BNP was relatively small;
we then simpliﬁed the path model. The results of the ﬁnally proposed
path analysis (standard regression coefﬁcients, squared multiple
correlations, and correlations among exogenous variables between
each clinical factor) are summarized in Fig. 4B and Table 4B. The ﬁnal
structure equation modeling showed a good ﬁt as follows: chi-square
minimum discrepancy/degree of freedom ratio (CMIN/DF) = 1.364
(≤2.000 is for a good ﬁt model, P = 0.182), goodness of ﬁt index
(GFI) = 0.989 (≥0.900 is for a good ﬁt model), adjusted goodness of
ﬁt index (AGFI) = 0.972 (≥0.900 is for a good ﬁt model), comparative
ﬁt index (CFI) = 0.998 (≥0.900 is for a good ﬁt model), parsimonious
comparative ﬁt index (PCFI) = 0.523, non-centrality parameter
(NCP) = 4.006 (90% conﬁdence interval [CI], 0 to 18.338), minimum
value of the discrepancy function F (FMIN) = 0.040 (90% CI, 0 to
0.049), root mean square error of approximation (RMSEA) = 0.031
(≤0.050 is for a good ﬁt model, 90% CI, 0 to 0.067), Akaike's information
criterion (AIC)= 49.006, and expected cross-validation index (ECVI)=
0.132 (90% CI, 0.121 to 0.171). There was a direct signiﬁcant association
of log pre-BNP with log post-BNP (unstandardized regression
coefﬁcients, β: 0.387, P b 0.001), pre-Cr (β: 0.067, P b 0.001), LVEF (β:
−0.005, P b 0.001), post-BMI (β:−0.043, P b 0.001), and pre-BMI (β:
0.030, P = 0.007). It is important that the post-BMI was inversely
correlated with the log pre-BNP, whereas the pre-BMI was positively
correlated with the log pre-BNP. This is probably because the pre-BMI
entailed an element of ﬂuid accumulation, which would increase the
pre-BNP. This suggests that obesity itself substantially suppressed an
increase in the plasma BNP levels in acute heart failure. It is also inter-
esting to see that the absolute inﬂuence of obesity on the plasma BNP
levels matched that of LVEF, a probablemajor component of an increase
in the plasma BNP levels.
3.5. The distribution patterns of obese and nonobese patients according to
the degree of plasma BNP levels in the acute phase of heart failure
The result of pass analysis indicated that the post-BMI, reﬂecting
obesity, would be important for determination of the log pre-BNP. We
then examined the number of obese patients according to the plasma
BNP level in the acute phase. Using Fig. 4A showing the histogram for
pre-BNP, the distribution patterns of the study population were
examined by dividing patients into obese (post-BMI ≧ 25) and nonobese
Fig. 1. Single regression analysis. (A) Single regression analysis for pre-BMI and log pre-BNP before treatment. (B) Single regression analysis for post-BMI and log post-BNP before
treatment. These panels show the single regression lines (oblique center lines) and the 95th percentile lines (oblique parallel lines) in scatter plots. These equations indicate the single
regression formulas. Pre-BMI means BMI before treatment. Log pre-BNP means the natural logarithmically-converted pre-BNP before treatment. Post-BMI means BMI after treatment.
Log post-BNP means the natural logarithmically-converted BNP after treatment. R2: squared Pearson's correlation coefﬁcient; BMI: body mass index; BNP: B-type natriuretic peptide.
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of patients with a level less than 500 pg/mL, 23%with a level 500 pg/mL,
17%with a level 1000 pg/mL, 5%with a level 2000 pg/mL, and 0%with a
level 3000pg/mL and over. This result suggests that therewere few very
obese patients among the group with high plasma BNP levels in the
acute phase of heart failure. The absolute inﬂuence of obesity on plasma
BNP levels might surpass that of cardiac dysfunction, renal dysfunction,
and other factors among patients with severe obesity.3.6. The distribution patterns of patients with low and high plasma BNP
levels in the acute phase of heart failure according to the degree of obesity
Fig. 4B shows the histogram for post-BMI.We examined the number
of patients with low and high plasma BNP levels (pre-BNP) in the acute
phase of heart failure according to the degree of obesity (post-BMI). The
distribution patterns of the study population were examined by divid-
ing patients into groups who had extremely high pre-BNP (pre-BNP
≥200 pg/mL) and others (pre-BNP b200 pg/mL), as shown in Fig. 4D.
BMI less than 15 kg/m2 was present in 26% of patients with extremely
high pre-BNP, 16% in the group with BMI 15 kg/m2, 6% in the group
with BMI 20 kg/m2, 0.1% in the group with BMI 25 kg/m2, and 0% in
the group with BMI 30 kg/m2 and over. This result also suggested that
there were few obese patients with high plasma BNP levels in the
acute phase of heart failure.Table 2
The results of multiple regression analysis to identify the clinical factors inﬂuencing the logarit
A. Model for log pre-BNP (R2 = 0.230) Regression coefﬁcient Standard
Age 0.002 0.085
Gender −0.057 −0.069
Pre-BMI −0.016 −0.199
Pre-creatinine 0.107 0.291
LVEF −0.007 −0.314
Constant 3.256 –
B. Model for log post-BNP (R2 = 0.186)
Age 0.008 0.257
Gender 0.038 0.036
Post-BMI −0.022 −0.203
Post-creatinine 0.080 0.198
LVEF −0.005 −0.183
Constant 2.374 –
R2, adjusted coefﬁcient of determination; BMI, body mass index; BNP, B-type natriuretic peptid
conﬁdence interval; VIF, variance inﬂation factor.4. Discussion
In order to use plasma BNP levels to evaluate heart failure more ef-
fectively and accurately in routine emergency medical care, it is neces-
sary to examine the factors inﬂuencing the levels. Thus, it would be
important to examine the extent towhich obesity negatively inﬂuences
plasma BNP levels in acute heart failure. If the impact of obesity on plas-
ma BNP levels is high, the attending physician should monitor patients
with increased BMI very carefully, to avoid underestimating the degree
of heart failure when using BNP.
The tendency toward an inverse relationship between obesity and
low plasma BNP levels was reported by Wang et al. [13] and others [6,
7,14]. We also investigated the degree of inﬂuence of obesity on plasma
BNP levels, and examined the relationship between the BNP level and
BMI in patients who were admitted to our cardiovascular unit [15].
The BMI was a signiﬁcant factor reducing plasma BNP levels, and its im-
pact signiﬁcantly increased in relation to the BMI value. However, BMI
in that study was measured at only one point in patients admitted to
our institution with and without acute heart failure. Therefore, the
true impact of obesity on plasma BNP levels might have remained un-
clear because the component of ﬂuid accumulation was not taken into
account in that study. Furthermore, the inﬂuence of other factors on
the plasma BNP level may not have been adequately examined. Thus,
a high level of statistical analysis is warranted to discuss the importance
of obesity on plasma BNP levels.hmic pre-BNP and post-BNP levels (in upper and lower tables, respectively).
regression coefﬁcient P-value 95% CI VIF
0.118 −0.001 to 0.005 1.402
0.147 −0.135 to 0.020 1.090
b0.001 −0.024 to−0.008 1.210
b0.001 0.073 to 0.140 1.041
b0.001 −0.010 to−0.005 1.201
b0.001 2.955 to 3.556 –
b0.001 0.005 to 0.011 1.393
0.457 −0.062 to 0.137 1.090
b0.001 −0.032 to−0.011 1.193
b0.001 0.042 to 0.118 1.032
b0.001 −0.008 to−0.002 1.200
b0.001 1.998 to 2.750 –
e; Pre-, before treatment; Post-, after treatment; LVEF, left ventricular ejection fraction; CI,
Fig. 2. Explanatory drawing of possible link between BMI and plasma BNP levels before and after treatment.Multiple regression analysis showed a signiﬁcant correlation between BMI and
plasma BNP levels before and after treatment; however, the link between post-BMI and pre-BNP was unclear in multiple regression analysis. Pre-BMI means BMI before treatment. Pre-
BNP means BNP levels before treatment. Post-BMI means BMI after treatment. Post-BNP means BNP levels after treatment. BMI: body mass index; BNP: B-type natriuretic peptide.
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correlation between the BMI and plasma BNP levels both before and
after treatment for acute heart failure, by single andmultiple regression
analysis (also see Table 3). This result suggests that BMI suppresses
plasma BNP levels regardless of the patient's condition before and
after treatment. Thiswould support previousﬁndings; however, the im-
pact of obesity on plasma BNP levels in the acute phase of heart failure
remained unclariﬁed because the pre-BNP, post-BNP, pre-BMI, post-
BMI, and other parameters were statistically related in a complex man-
ner, as shown in Fig. 2. It would be theoretically difﬁcult to compare the
relationship using multiple regression analysis alone.
In order to examine the true inﬂuence of obesity on plasma BNP in
the acute phase of heart failure, we proposed covariance structure
analysis. In this study, we ﬁrst proposed a path model as shown in
Fig. 3A. We then adjusted the model for better ﬁt. Finally, we showed
the successful ﬁnal model as shown in Fig. 3B. Interestingly, there was
a signiﬁcant positive correlation between the pre-BMI and the log pre-
BNP, probably because the pre-BMI entailed an element of ﬂuid accu-
mulation, whereas there was a signiﬁcant inverse correlation between
the post-BMI and the log pre-BNP. This indicated for the ﬁrst time the
true effect of obesity on plasma BNP levels in acute heart failure; obesity
substantially interfered with the positive inﬂuence on the increase in
plasma BNP levels caused by cardiac dysfunction, body ﬂuid excess,
renal dysfunction, and other factors. The absolute inﬂuence would
compete with other major components.
The current information obtained from path analysis can be useful in
routine clinical settings. For example, if a symptomatic patient has an in-
creased BMI but the concurrent plasmaBNP level is relatively low, the phy-
sician might not consider heart failure in the diagnosis. This is of concern
because theplasmaBNP cannot increase, even inheart failure, if thepatient
has true obesity. On the other hand, if the plasma BNP levels are high in a
patient with increased BMI, the patient may not be obese, but may
simply have ﬂuid accumulation. Diuretics may be able to reduce the
excess body weight and simultaneously decrease the plasma BNP level.Table 3
The results of Pearson product–moment correlation coefﬁcient analysis to identify the clinical
R (n = 372) Age Pre-BMI Log pre-BNP Pre-C
Pre-BMI −0.383† – −0.260† −0.1
Log pre-BNP 0.092 −0.260† – 0.3
Post-BMI −0.369† 0.961† −0.297† −0.0
Log post-BNP 0.283† −0.289† 0.592† 0.2
R, Pearson's correlation coefﬁcient; BMI, bodymass index; BNP, B-type natriuretic peptide; Cr, c
tion; P value: *, P b 0.05; †, P b 0.001; no mark, not signiﬁcant.In the current study, statistical analysis revealed an inverse
correlation between plasma BNP levels and BMI. It is important to
discuss the pathophysiological function of adipocytes and their relation-
ship to a decrease in plasma BNP levels. First, it is probable that
natriuretic peptide reduces BMI by improving the function of
adipocytes. Second, it is likely that unknown factors secreted by
adipocytes attenuate theproductionof BNP in theheart and/or augment
BNP clearance in the body. Although it is unclear which mechanism is
predominant, it is conceivable that these pathways aremutually related
as follows.
It can be assumed that a high BNP level plays a causative role in
lowering BMI. In this regard, there is an important report using BNP
transgenic mice that showed that NP/cGK cascades promote muscle
mitochondrial biogenesis and fat oxidation via the upregulation of
PGC-1α and peroxisome proliferator-activated receptor (PPAR) γ,
thus preventing obesity and glucose intolerance [16]. It is thus possible
to suppose that an increase in BNP secretion accelerates lipolysis in
adipocytes, resulting in a low BMI. On the other hand, it is conceivable
that a high degree of obesity plays a causative role in lowering the
plasma BNP level. It has been reported that the heart utilizes fatty
acids mainly as an energy source in patients with obesity, with the
concomitant suppression of glucose utilization via the activation of
PPARα [17,18]. It is also interesting that PPARα suppresses BNPproduc-
tion [19]. Therefore, it is conceivable that increased plasma free fatty
acid availability suppresses BNP production. In addition, it has been
demonstrated that hypoxia-inducible factor (HIF) 1α plays a crucial
role in BNP production [20,21]. Insulin induces HIF-1α [22,23] and it is
therefore conceivable that BNP production is reduced under conditions
of insulin resistance via HIF-1α suppression in obese patients, as
discussed previously [24,25].
At present, it is unclear whether the substantial link between fat
accumulation/obesity and low BNP levels is favorable or unfavorable
in heart failure, but this should be investigated in the future for a
possible therapy based on this phenomenon. However, a recent studyfactors inﬂuencing the logarithmic pre-BNP and post-BNP levels.
r Post-BMI Log post-BNP Post-Cr LVEF
10* 0.961† −0.289† −0.065 −0.047
25† −0.297† 0.592† 0.292† −0.268†
95 – −0.296† −0.055 −0.039
70† −0.296† – 0.244† −0.084
reatinine; Pre-, before treatment; Post-, after treatment; LVEF, left ventricular ejection frac-
Fig. 3.Passmodels. (A) Passmodel theoretically proposed. (B) Passmodelmodiﬁed for bestﬁt. Eachpath has a coefﬁcient showing the standardized coefﬁcient of a regressing independent
variable on a dependent variable of the relevant path. These variables mean standardized regression coefﬁcients (direct effect) [underlined parts mean remarkable values], squared
multiple correlations [in narrow italics] and correlations among exogenous variables [inside round brackets]. BMI: body mass index; BNP: B-type natriuretic peptide; LVEF; left
ventricular ejection fraction; Cr: creatinine kinase; e: extraneous variable.
288 K. Kinoshita et al. / International Journal of Cardiology 215 (2016) 283–290reported that an increase in production of endogenous natriuretic pep-
tide is beneﬁcial for energy efﬁciency in obese patients; drugs that
inhibited the degradation of natriuretic peptide were beneﬁcial for
heart failure [26]. In addition, we recently reported that plasma BNPTable 4
The results of standardized regression coefﬁcient analysis to identify the clinical factors inﬂuen
BNP Clinical factor Direc
(A) Pass model theoretically proposed
Log pre-BNP ← Log post-BNP 0.4
← Pre-BMI 0.3
← Post-BMI −0.4
← Age −0.0
← Gender −0.0
← LVEF −0.2
← Pre-Cr 0.1
← Post-Cr 0
Log post-BNP ← Post-BMI −0.2
← Age 0.2
← Gender 0.0
← LVEF −0.1
← Post-Cr 0.1
Pre-BMI ← Post-BMI 0.9
The results (direct, indirect, and total effects) of the pass model theoretically proposed (A)
inﬂuencing both the logarithmic post-BNP and pre-BNP levels (see Fig. 3).
(B) Pass model modiﬁed for the best ﬁt (removed “age and gender”)
Log pre-BNP ← Log post-BNP 0.4
← Pre-BMI 0.3
← Post-BMI −0.5
← LVEF −0.2
← Pre-Cr 0.1
← Post-Cr 0
Log post-BNP ← Post-BMI −0.2
← LVEF −0.0
← Post-Cr 0.2
Pre-BMI ← Post-BMI 0.9
The standardized total (direct and indirect) effect of each variable on both pre-BNP and post-B
BMI, body mass index; BNP, B-type natriuretic peptide; Cr, creatinine; Pre-, before treatment;levels were inversely associated with insulin resistance in patients
with chronic heart failure [25].We also reported that low plasma levels
of BNP were signiﬁcantly associated with ischemic heart disease [27].
These new ﬁndings would indicate that an increase in the productioncing the logarithmic pre-BNP and post-BNP levels in each pass model.
t effect Indirect effect Total effect
92 0 0.492
60 0 0.360
92 0.245 −0.247
47 0.128 0.081
76 0.018 −0.058
22 −0.091 −0.313
93 0 0.193
0.098 0.098
05 0 −0.205
59 0 0.259
37 0 0.037
84 0 −0.184
99 0 0.199
61 0 0.961
and the pass model modiﬁed for the best ﬁt (B) analysis to identify the clinical factors
84 0 0.484
74 0 0.374
06 0.220 −0.286
26 −0.047 −0.274
83 0 0.183
0.111 0.111
88 0 −0.288
98 0 −0.098
30 0 0.230
61 0 0.961
NP levels after standardizing all variables.
Post-, after treatment; LVEF, left ventricular ejection fraction.
Fig. 4.Histograms and distribution of study patients according to pre-BNP and post-BMI. (A) The histogram for patient numbers according to plasma BNP levels before treatment for heart
failure. (B) The histogram for patient numbers according to BMI after treatment for heart failure. (C) The distribution patterns of obese and nonobese patients according to the plasma BNP
level in the acute phase of heart failure. *Pb 0.05 vs. 0–500,☨P b 0.05 vs. 500–1000. (D) Thedistribution patterns of patientswith low andhighplasmaBNP levels in the acute phase of heart
failure according to the degree of obesity. *P b 0.05 vs. 0–15. Pre-BNPmeans the plasma BNP levels before treatment. Post-BMImeans BMI after treatment. BMI: bodymass index; BNP: B-
type natriuretic peptide.
289K. Kinoshita et al. / International Journal of Cardiology 215 (2016) 283–290of BNP is beneﬁcial for energy metabolism and suppression of ischemic
heart disease, although more detailed study is necessary.
5. Conclusion
The current path analysis logically showed that obesity itself strong-
ly suppressed plasmaBNP levels in acute heart failure. If the plasmaBNP
levels are high in a patientwith increased BMI, the patientmay not have
true obesity but simply have ﬂuid accumulation. On the other hand, a
patient with an increased BMI but a low plasma BNP level is of concern,
because the plasma BNP cannot increase, even in heart failure, if the pa-
tient has true obesity. Knowledge of the pathophysiological mecha-
nisms of the strong link between obesity and low natriuretic peptide
levels, which remain unclear, would be of value for future research on
energy metabolism in heart failure.
6. Study limitations
Therewere some study limitations. First, we examined serial plasma
BNP levels in 372 patients during treatment for acute heart failure and
showed that levels seldom increased in obese patients even with se-
verely reduced cardiac function. However, it is still undetermined
whether plasma BNP levels are actually limited to an increase in obese
patientswith very severe cardiac dysfunction during the terminal stages
of heart failure. Second, we proposed andmodiﬁed a pathmodel for the
best ﬁt; however, the current predictors of pre-BNP were explained by
only 45.1% of the variance. Other path models may be better and we
may have to modify the current model. For example, the LVEF wasmeasured at only one point before admission. However, the LVEF
would change slightly during treatment. The LVEF after treatment
would be useful for the purposes of accuracy. Moreover, we previously
reported that the left ventricular end-systolic volume index (LVESVI)
was associated with plasma BNP levels more sensitively than the LVEF
[3]. Unfortunately, we had no data for the LVESVI in this study. If the
LVESVI is used in a path analysis, the estimates of squared multiple cor-
relations for the pre-BNP would be further improved.Funding sources
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